Genprex, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.67
- 52-Week Range
- $1.63 – $80.96
- Market Cap
- $2.28M
- P/E (TTM)
- —
- EPS (TTM)
- -9.35
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.15
- PEG Ratio
- —
- Return on Equity
- -233.73%
- Return on Assets
- -99.41%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 4.26
- Debt/Equity
- —
- Total Debt
- $0.00
- Free Cash Flow
- $-9.99M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $-13.06M
Market Snapshot
About
Genprex, Inc. is a clinical-stage biopharmaceutical company developing targeted gene therapies for cancer and diabetes. The company's lead oncology candidate Reqorsa is a tumor suppressor gene therapy delivered through a proprietary nanoparticle delivery system for treatment of non-small cell lung cancer. Genprex is also developing Oncoprex immunogene therapy and diabetes treatment GPX-002 using its TUSC2 nanoparticle technology platform. The company's approach focuses on delivering therapeutic genes directly to diseased tissues while minimizing systemic exposure.